Rituximab in secondary progressive multiple sclerosis: a meta-analysis.
Pasin IntarakhaoTaksaporn LaipasuJiraporn JitprapaikulsanNatnasak ApiraksattayakulPunchika KosiyakulSasitorn SirithoNaraporn PrayoonwiwatTatchaporn OngphichetmethaPublished in: Annals of clinical and translational neurology (2024)
RTX demonstrates efficacy in reducing relapse frequency and exhibits potential in stabilizing disability progression over a 2-year follow-up, particularly among individuals with shorter disease duration.